tiprankstipranks
Advertisement
Advertisement

Lonza Raises Dividend, Refreshes Board and Publishes 2025 Reports Ahead of 2026 AGM

Story Highlights
  • Lonza published its 2025 Annual and Sustainability Reports and set its 2026 AGM for 8 May in Basel, outlining strategy, performance and ESG progress.
  • Lonza plans a 25% dividend hike and significant Board refresh, signaling confidence in earnings and bolstering expertise in healthcare, automation and biopharma.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Lonza Raises Dividend, Refreshes Board and Publishes 2025 Reports Ahead of 2026 AGM

Meet Samuel – Your Personal Investing Prophet

Lonza Group Ltd ( (CH:LONN) ) has provided an update.

Lonza has published its 2025 Annual and Sustainability Reports and issued the invitation to its 2026 Annual General Meeting, to be held on 8 May in Basel. The reports detail strategic direction, business structure, financial performance, governance and sustainability progress, with the sustainability report aligned to Global Reporting Initiative standards.

The company is proposing a 25% dividend increase to CHF 5.00 per share, half of which would be paid from capital contribution reserves and thus exempt from Swiss withholding tax. Board changes include the proposed re-election of Chair Jean-Marc Huët, the departure of three directors, and the nomination of three new members bringing deep expertise in healthcare, life sciences, automation, AI and biopharma leadership.

These governance and capital-allocation measures signal Lonza’s confidence in its earnings power and long-term strategy after a solid 2025 performance. The addition of directors with strong healthcare, Asian market, automation and human-capital credentials may strengthen Lonza’s industry positioning and support future growth in complex biologics manufacturing and related services.

The most recent analyst rating on (CH:LONN) stock is a Hold with a CHF481.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.

More about Lonza Group Ltd

Lonza Group is the world’s largest contract development and manufacturing organization focused on the healthcare industry. Operating across five continents with around 20,000 employees, it partners with pharma and biotech companies to turn innovations into commercial therapies, generating CHF 6.5 billion in 2025 sales and CHF 2.1 billion in CORE EBITDA.

Average Trading Volume: 168,809

Technical Sentiment Signal: Hold

Current Market Cap: CHF33.97B

Find detailed analytics on LONN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1